Cited by 394Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 156 of the 159 references it cites were found in a registry or an index.

Emerging diagnostics and therapeutics for Alzheimer disease

Self, Wade K., Holtzman, David M.·2023·Nature Medicine

DOI 10.1038/s41591-023-02505-2

Open this paper in CoChat — free account

Abstract

Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently. This Review highlights the latest advances in biomarker technologies and therapeutic development to improve AD diagnosis and treatment. We review recent results that enable pathological staging of AD with neuroimaging and fluid-based biomarkers, with a particular emphasis on the role of amyloid, tau and neuroinflammation in disease pathogenesis. We discuss the lessons learned from randomized controlled trials, including some supporting the proposal that certain anti-amyloid antibodies slow cognitive decline during the mildly symptomatic phase of AD. In addition, we highlight evidence for newly identified therapeutic targets that may be able to modify AD pathogenesis and progression. Collectively, these recent discoveries-and the research directions that they open-have the potential to move AD clinical care toward disease-modifying treatment strategies with maximal benefits for patients.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02505-2

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Retracted
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citation
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Self-citation
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

Show all 159 references

Research works printed but not linked: 1

ALZFORUM. Gantenerumab mystery: how did it lose potency in phase 3? https://www.alzforum.org/news/conference-coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3

Sorted by citations

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 346
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
Innate immune activation in neurodegenerative diseases
Castro‐Gomez, S., & Heneka, M. T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.010 · Cited by 176
The six brain‐specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
Buchholz, S., & Zempel, H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13784 · Cited by 154
Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer’s Disease
Jiang, S., Cai, G., Yang, Z., Shi, H., Zeng, H., Ye, Q., Hu, Z., & Wang, Z. (2024) · ACS Nano · doi:10.1021/acsnano.3c13150 · Cited by 135
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.029 · Cited by 120
Self-citation
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank
Wang, X., Shi, Z., Qiu, Y., Sun, D., & Zhou, H. (2024) · BMC Medicine · doi:10.1186/s12916-024-03418-8 · Cited by 126
Lecanemab Treatment in a Specialty Memory Clinic
Paczynski, M., Hofmann, A., Posey, Z. J., Gregersen, M., Rudman, M., Ellington, D., Aldinger, M., Musiek, E. S., Holtzman, D. M., Bateman, R. J., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1232 · Cited by 116
Self-citation
Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease
Conn, K. A., Borsom, E. M., & Cope, E. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2371950 · Cited by 106
The neuroimmune nexus: unraveling the role of the mtDNA-cGAS-STING signal pathway in Alzheimer’s disease
Quan, S., Fu, X., Cai, H., Ren, Z., Xu, Y., & Jia, L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00815-2 · Cited by 110
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
Wolk, D. A., Nelson, P. T., Apostolova, L. G., Arfanakis, K., Boyle, P. A., Carlsson, C. M., Corriveau‐Lecavalier, N., Dacks, P. A., Dickerson, B. C., Domoto‐Reilly, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14202 · Cited by 103
Sex-dependent APOE4 neutrophil–microglia interactions drive cognitive impairment in Alzheimer’s disease
Rosenzweig, N., Kleemann, K. L., Rust, T., Carpenter, M., Grucci, M., Aronchik, M., Brouwer, N., Valenbreder, I., Cooper-Hohn, J., Iyer, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03122-3 · Cited by 90
Lanthanide-bimetallic organic frameworks: from mechanism and sensors design to ratiometric fluorescent applications
Zhou, J., Hu, X., Liu, C., Liu, Y., Tian, N., Wu, F. Y., Li, W., Lei, J., & Dai, Z. H. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216574 · Cited by 92
Artificial intelligence for drug discovery and development in Alzheimer's disease
Qiu, Y., & Cheng, F. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102776 · Cited by 83
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis
Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78
Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease
Rajani, R. M., Ellingford, R., Hellmuth, M., Harris, S. S., Taso, O. S., Graykowski, D., Lam, F. K. W., Arber, C., Fertan, E., Danial, J. S. H., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002727 · Cited by 62
“While recent anti-A β antibody therapies targeting plaques have been shown to be effective in slowing the clinical course of AD, they can lead to blood vessel damage, detected as amyloid-related imaging abnormalities (ARIA) on MRI [53].”
Background
Cryo-EM structures of Aβ40 filaments from the leptomeninges of individuals with Alzheimer’s disease and cerebral amyloid angiopathy
Yang, Y., Murzin, A. G., Peak‐Chew, S., Franco, C., Garringer, H. J., Newell, K. L., Ghetti, B. F., Goedert, M., & Scheres, S. H. W. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01694-8 · Cited by 60
Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflammation in Alzheimer’s disease
Song, Z., Xie, X., Chen, Y., Zhang, B., Li, X., Yang, Y., Mo, W., Zhang, J., & Xu, D. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.024 · Cited by 62
Adaptive immune changes associate with clinical progression of Alzheimer’s disease
van Olst, L., Kamermans, A., Halters, S., van der Pol, S. M. A., Rodríguez, E., Verberk, I. M. W., Verberk, S. G. S., Wessels, D. W. R., Rodriguez-Mogeda, C., Verhoeff, J., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00726-8 · Cited by 61
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
Hatano, T., Okuzumi, A., Matsumoto, G., Tsunemi, T., & Hattori, N. (2024) · Journal of Movement Disorders · doi:10.14802/jmd.24075 · Cited by 49
The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity
Arslan, B., Brum, W. S., Pola, I., Therriault, J., Rahmouni, N., Stevenson, J., Servaes, S., Tan, K., Vitali, P., Montembeault, M., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01692-z · Cited by 61
Metagenomic analysis characterizes stage-specific gut microbiota in Alzheimer’s disease
Jia, L., Ke, Y., Zhao, S., Liu, J., Luo, X., Cao, J., Liu, Y., Guo, Q., Chen, W., Chen, F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02973-7 · Cited by 52
Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies
Langerscheidt, F., Wied, T., Kabbani, M. A. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 52
Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Hou, J., Chen, Y., Cai, Z., Heo, G. S., Yuede, C. M., Wang, Z., Lin, K., Saadi, F., Tršan, T., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9052 · Cited by 44
Self-citation
Astrocyte and oligodendrocyte pathology in Alzheimer's disease
Ziar, R., Tesar, P. J., & Clayton, B. L. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00540 · Cited by 47
SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis
Ouyang, P., Cai, Z., Peng, J., Lin, S., Chen, X., Chen, C., Feng, Z., Wang, L., Song, G.-L., & Zhang, Z. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103064 · Cited by 40
Rational structural design of aromatic Azo photoactive small molecules for biomedical applications
Ding, J., Huang, Z. H., Zhang, D., Qu, Y., Zhang, S., Zhang, C., Fang, B., Li, L., & Huang, W. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00334b · Cited by 38
Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease
Dicarlo, M., Pignataro, P., Zecca, C., Dell’Abate, M. T., Urso, D., Gnoni, V., Giugno, A., Borlizzi, F., Zerlotin, R., Oranger, A., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26946 · Cited by 37
Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer’s disease
Hofmann, A., Häsler, L. M., Lambert, M., Kaeser, S. A., Gräber‐Sultan, S., Obermüller, U., Kuder-Buletta, E., la Fougère, C., Laske, C., Vöglein, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52937-8 · Cited by 45
Self-citation
The neurotransmitter puzzle of Alzheimer's: Dissecting mechanisms and exploring therapeutic horizons
Sharma, M., Pal, P., & Gupta, S. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148797 · Cited by 34
Phototherapy via Modulation of β‐Amyloid in Combating Alzheimer's Disease
Zhang, Y., Qian, C., Chen, Y., He, W., & Guo, Z. (2025) · Aggregate · doi:10.1002/agt2.70020 · Cited by 31
Deciphering proteins in Alzheimer’s disease: A new Mendelian randomization method integrated with AlphaFold3 for 3D structure prediction
Yao, M., Miller, G. W., Vardarajan, B. N., Baccarelli, A., Guo, Z., & Liu, Z. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100700 · Cited by 35
Association between periodontitis and Alzheimer's disease: A narrative review
Seyedmoalemi, M., & Saied‐Moallemi, Z. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.004 · Cited by 29
Early-stage Alzheimer’s disease profiling in blood achieved by multiplexing aptamer-SERS biosensors
Muhammad, M., Liu, C., Ge, Y., Shao, C., Xiong, L., Xia, H., Iqbal, J., Zhan, J., Qu, F., & Huang, Q. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116907 · Cited by 28
Beyond the usual suspects: multi-factorial computational models in the search for neurodegenerative disease mechanisms
Khan, A. F., & Iturria‐Medina, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03073-w · Cited by 31
Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis
Antonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 34
Unlocking therapeutic potential: the role of adamantane in drug discovery
Dane, C., Cumbers, G. A., Allen, B. M., Montgomery, A. P., Danon, J. J., & Kassiou, M. (2024) · Australian Journal of Chemistry · doi:10.1071/ch24075 · Cited by 26
Omnidirectional improvement of mitochondrial health in Alzheimer's disease by multi-targeting engineered activated neutrophil exosomes
Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26
Pharmacological effects, molecular mechanisms and strategies to improve bioavailability of curcumin in the treatment of neurodegenerative diseases
Wang, G., Zhou, X., Pang, X., Ma, K., Li, L., Song, Y., Hou, D., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1625821 · Cited by 28
Blood biomarkers of Alzheimer’s disease and progression across different stages of cognitive decline in the community
Valletta, M., Vetrano, D. L., Gregorio, C., Rizzuto, D., Winblad, B. G., Canevelli, M., Andersson, S., Dale, M., Fredolini, C., Laukka, E. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66728-2 · Cited by 36
Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function
Sadlon, A., Takousis, P., Ankli, B., Alexopoulos, P., Perneczky, R., & Initiative, A. D. N. (2023) · Annals of Neurology · doi:10.1002/ana.26804 · Cited by 26
APOE3ch alleviates Aβ and tau pathology and neurodegeneration in the human APPNL-G-F cerebral organoid model of Alzheimer’s disease
Liu, H., Mei, F., Ye, R., Han, X., Wang, S., Ding, Y., Zhi, Y., Pang, K., Guo, W., & Lu, B. (2024) · Cell Research · doi:10.1038/s41422-024-00957-w · Cited by 27
Roseburia intestinalis Supplementation Could Reverse the Learning and Memory Impairment and m6A Methylation Modification Decrease Caused by 27-Hydroxycholesterol in Mice
Sun, X., Zhou, C. L., Ju, M., Feng, W., Guo, Z., Qi, C., Yang, K., & Xiao, R. (2024) · Nutrients · doi:10.3390/nu16091288 · Cited by 26
Advanced biomarkers: Beyond amyloid and tau: Emerging non-traditional biomarkers for alzheimer`s diagnosis and progression
Afrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102736 · Cited by 27
Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway
Zhai, Y., Lu, K., Yuan, Y., Zhang, Z., Xue, L., Zhao, F., Xu, X., & Wang, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329439 · Cited by 24
FDCNN-AS: Federated deep convolutional neural network Alzheimer detection schemes for different age groups
Lakhan, A. R., Mohammed, M. A., Ghani, M. K. A., Abdulkareem, K. H., Marhoon, H. A., Nedoma, J., Martínek, R., & Deveci, M. (2024) · Information Sciences · doi:10.1016/j.ins.2024.120833 · Cited by 22
Development of donepezil hydrochloride-loaded PLGA-based nanoparticles for Alzheimer’s disease treatment
Kömür, M., Kıyan, H. T., & Öztürk, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95792-3 · Cited by 22
Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy
Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 28
Self-citation
Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
Marvi, F., Chen, Y.-H., & Sawan, M. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2024.3376835 · Cited by 24
Edaravone Dexborneol ameliorates the cognitive deficits of APP/PS1 mice by inhibiting TLR4/MAPK signaling pathway via upregulating TREM2
Wang, J., Du, L., Zhang, T., Chu, Y., Wang, Y., Wang, Y. T., Ji, X., Kang, Y., Cui, R., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110006 · Cited by 22
Porphyromonas gingivalis and Its Outer Membrane Vesicles Induce Neuroinflammation in Mice Through Distinct Mechanisms
Qiu, Y. L., Zhao, Y., He, G., & Yang, D. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70135 · Cited by 24
Alzheimer’s disease and age-related macular degeneration: Shared and distinct immune mechanisms
Butovsky, O., & Rosenzweig, N. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.013 · Cited by 22
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort
Gong, K., Timsina, J., Ali, M., Chen, Y., Liu, M., Wang, C., Pottier, C. P., Feld, G. K., Heo, G., Benzinger, T. L. S., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00909-x · Cited by 26
Self-citation
Gut microbiota metabolites: potential therapeutic targets for Alzheimer’s disease?
Zhang, S., Lu, J., Jin, Z., Xu, H., Zhang, D., Chen, J., & Wang, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1459655 · Cited by 25
New insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies
Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19
Self-citation
Fueling the fight against cancer: Exploring the impact of branched-chain amino acid catalyzation on cancer and cancer immune microenvironment
Ma, Q., Li, H., Song, Z., Deng, Z., Huang, W., & Liu, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156016 · Cited by 19
ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine
Quan, Z., Wang, S., Xie, H., Zhang, J., Duan, R., Li, M., & Zhang, J. (2024) · Small · doi:10.1002/smll.202410031 · Cited by 18
Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 24
Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090724 · Cited by 21
Advancements in Pharmacological Treatment of Alzheimer’s Disease: The Advent of Disease-Modifying Therapies (DMTs)
Wang, Q., Chen, S., Wang, J., Shang, H., & Chen, X. (2024) · Brain Sciences · doi:10.3390/brainsci14100990 · Cited by 18
Regulation of STING G-quadruplex for rescuing cellular senescence and Aβ phagocytic capacity of microglia
Yuan, H., Yang, J., Qin, G., Sun, Y., Zhao, C., Wang, C., Ren, J., & Qu, X. (2024) · Chemical Science · doi:10.1039/d4sc04453c · Cited by 17
A Self‐Reinforced “Microglia Energy Modulator” for Synergistic Amyloid‐β Clearance in Alzheimer's Disease Model
Ma, M., Wang, J., Guo, K., Zhong, W., Cheng, Y., Lin, L., & Zhao, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202420547 · Cited by 18
Rational Design of Long-Circulating Bright Fluorescent Probe for In Vivo Imaging of Amyloid-β Plaques in Alzheimer’s Disease
Chen, J., Wang, X., Liu, X., Shi, L., Yu, X., Cen, X., & Li, K. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01619 · Cited by 16
Photothermal and Photodynamic Strategies for Diagnosis and Therapy of Alzheimer’s Disease by Modulating Amyloid-β Aggregation
Gao, F., Hou, Y., Wang, Y., Liu, L., Yi, X., & Xia, N. (2025) · Biosensors · doi:10.3390/bios15080480 · Cited by 15
Immunity in Alzheimer’s disease: From mechanisms to therapies
Chen, X., Holtzman, D. M., & Colonna, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.004 · Cited by 18
Self-citation
Alzheimer’s disease and immunotherapy
Qin, W., Pang, Y., Nie, S., Quan, M., & Jia, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00035-8 · Cited by 15
Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis
Oddi, S., Scipioni, L., Totaro, A., Giacovazzo, G., Ciaramellano, F., Tortolani, D., Leuti, A., Businaro, R., Armeli, F., Bilkei‐Gorzó, A., et al. (2025) · FEBS Journal · doi:10.1111/febs.17403 · Cited by 14
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up
Knezović, A., & Šalković‐Petrišić, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02887-2 · Cited by 15
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease
Yan, Z.-J., Ye, M., Li, J., Zhang, D., & Yao, Y. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00853-w · Cited by 16
A systems approach uncovers drivers of the multifocal emergence of an astrocyte state contributing to cognitive decline in Alzheimer’s diseasePreprint
Comandante-Lou, N., Lama, T. D., Heuer, S. E., Chen, K. W., Kim, J., Zhang, J., Hu, B., Liu, S., Dey, S., Brennand, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.24.639868 · Cited by 16
The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand
Thanapornsangsuth, P., Booncharoen, K., Khieukhajee, J., Luechaipanit, W., Haethaisong, T., Chongsuksantikul, A., Supharatpariyakorn, T., Chunharas, C., Likitjaroen, Y., & Hemachudha, T. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14138 · Cited by 12
Nasal nanotherapeutics for central nervous system disorders: Bridging the translational gap in central nervous system drug delivery
Zhang, Y.-B., Liu, M., Wang, Y., Hu, D., Wu, S., Zhao, B., Zhou, B., & Yang, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177958 · Cited by 14
ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14
Self-citation
Ultrasensitive Electrochemical Detection of Amyloid-β Peptide Using a Homochiral Metal–Organic Framework Binding to the l -Diphenylalanine Targeting Site
Li, R.-X., Shang, X. C., Shen, P.-Q., Zhu, Y., Gao, E., & Yue, Q. (2025) · ACS Sensors · doi:10.1021/acssensors.4c03425 · Cited by 13
Trichostatin A relieves anxiety-and depression-like symptoms in APP/PS1 mice
Su, Q., Ren, Y.-H., Liu, G.-W., Gao, Y., Zhang, J. Y., Zhang, J.-N., Pei, X.-X., & Li, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1333235 · Cited by 13
Extracellular vesicles‐based theranostics for neurodegenerative diseases
Zhao, H., Zhu, L., Wang, C., & Yang, Y. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1993 · Cited by 14
Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Barbosa, B. J. A. P., Resende, E. D. P. F., Castilhos, R. M., Borelli, W. V., Frota, N. A. F., Balthazar, M. L. F., Filho, A. C. S. A., Smid, J., Barbosa, M. T., Coutinho, A. M., et al. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-c002 · Cited by 17
Visualizing Endoplasmic Reticulum Stress and Autophagy in Alzheimer’s Model Cells by a Peroxynitrite-Responsive AIEgen Fluorescent Probe
Huang, L., Ma, L., Zhu, Q., Wang, H., She, G., Shi, W., & Mu, L. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00770 · Cited by 13
Therapeutic effects of long-term HBOT on Alzheimer's disease neuropathologies and cognitive impairment in APP/PS1 mice
Yang, C., Liu, G., Zeng, X., Xiang, Y., Chen, X., & Le, W. (2023) · Redox Biology · doi:10.1016/j.redox.2023.103006 · Cited by 12
Diagnosis of Alzheimer's disease: Towards accuracy and accessibility
Mu, Y., Chang, K., Chen, Y.-F., Yan, K., Wang, C.-X., & Hua, Q. (1970) · Journal of Biological Methods · doi:10.14440/jbm.2024.412 · Cited by 13
Dynamic prediction of goal location by coordinated representation of prefrontal-hippocampal theta sequences
Wang, Y., Wang, X., Wang, L., Li, Z., Meng, S., Zhu, N., An, X., Wang, L., Yang, J., Zheng, C., et al. (2024) · Current Biology · doi:10.1016/j.cub.2024.03.032 · Cited by 16
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Hadi, N. R., Assiri, A. A., Alrouji, M., Welson, N. N., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01489-y · Cited by 12
Acetylcholinesterase inhibitory phloroglucinols from tropic Rhodomyrtus tomentosa
Chen, L., Luo, E.-E., Pan, Y., Liang, C.-Q., Yu, M., & Qin, X. (2024) · Phytochemistry · doi:10.1016/j.phytochem.2024.114254 · Cited by 12
Photocatalytic, photothermal, and blood-brain barrier-permeable carbon nanodots: A potent multifunctional scavenger for β-amyloid plaque.
Shao, X., Li, M., Yan, C., Wang, C., Wang, X., Guan, P., Hu, X., & Fan, L. (2024) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114380 · Cited by 14
Nitrate ameliorates myelin loss and cognitive impairment in Alzheimer’s disease through upregulation of neuronal sialin and subsequent inhibition of TPPP phosphorylation
Chen, X., Hu, G., Chang, L., Li, X., Tang, Y., Wu, Y., Zhang, R., Zhang, C., Wang, J., Wang, X., et al. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.017 · Cited by 12
Supramolecular Copolymerization of Glycopeptide Amphiphiles and Amyloid Peptides Improves Neuron Survival
Gao, Z., Qiu, R., Dave, D. R., Chandravanshi, P., Soares, G. P., Smith, C. S., Ortega, J. A., Palmer, L. C., Álvarez, Z., & Stupp, S. I. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c00105 · Cited by 12
Synthetic efferocytic receptor microglia enhances anti-inflammatory clearance of amyloid-β for AD treatment in mice
Shao, L., Zhang, Y., Yang, Z., Shi, C., Yue, X., Li, C., Liu, Y., Fu, Z., Tang, C., Zhao, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads6613 · Cited by 13
Oxygen-enriching triphase platform for reliable sensing of femtomolar Alzheimer’s neurofilament lights
Song, Y., Kim, H., Lee, J., & Kim, K. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116431 · Cited by 11
Design, Synthesis, and Evaluation of New Pyrazolines As Small Molecule Inhibitors of Acetylcholinesterase
Altıntop, M. D., Sağlık, B. N., & Özdemır, A. (2024) · ACS Omega · doi:10.1021/acsomega.3c10490 · Cited by 11
Radix Hedysari Polysaccharides modulate the gut-brain axis and improve cognitive impairment in SAMP8 mice
Yang, S., Wang, L., Liang, X., Pei, T., Zeng, Y., Xie, B., Wang, Y., Yang, M., Wei, D., & Cheng, W. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141715 · Cited by 11
AΙ-Driven Drug Repurposing: Applications and Challenges
Keramida, P., Syrigos, N. K., Kouvela, M., Poulakou, G., Charpidou, A. G., & Fiste, O. (2025) · Medicines · doi:10.3390/medicines12040028 · Cited by 12
Indole-3-acetic acid, a potential therapeutic target in Alzheimer’s disease
Li, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.11.040 · Cited by 10
Potential neuroprotective benefits of plant-based fermented foods in Alzheimer's disease: an update on preclinical evidence
Chen, J., Yin, X., He, H., Lu, L. W., Wang, M., Liu, B., & Cheng, K. (2024) · Food & Function · doi:10.1039/d3fo03805j · Cited by 10
Activity-Based NIR Specific Fluorescent Probe Reveals the Abnormal Elevation of Prolyl Endopeptidase in Hippocampus during Alzheimer's Disease Progression
Li, H., Bian, K.-J., Wang, X.-Y., Li, X.-D., Song, P.-F., Yu, C., Ge, G.-B., Qian, X.-K., Zou, L.-W., Zhou, Y.-F., et al. (2024) · Sensors and actuators. B, Chemical · doi:10.1016/j.snb.2024.136071 · Cited by 10
Elucidating Microglial Heterogeneity and Functions in Alzheimer’s Disease Using Single-cell Analysis and Convolutional Neural Network Disease Model Construction
Wu, X., Liu, M., Zhang, X., Pan, X., Cui, X., Jin, J., Sun, H., Xiao, C., Tong, X., Ren, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67537-1 · Cited by 11
Spectral graph convolutional neural network for Alzheimer's disease diagnosis and multi-disease categorization from functional brain changes in magnetic resonance images
Alharbi, H. F., Juanatas, R. A., Hejaili, A. A., & Lim, S. (2024) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2024.1495571 · Cited by 12
The pathogenic APP N-terminal Val225Ala mutation alters tau protein liquid-liquid phase separation and exacerbates synaptic damage
Chen, J., Li, S., Zhang, F., Chen, J., Cai, C., Guo, Y., Lei, Z., Zeng, L., Zi, D., Shen, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02837-6 · Cited by 12
Exercise intervention on the brain structure and function of patients with mild cognitive impairment: systematic review based on magnetic resonance imaging studies
Xu, J., Yu, J., Gai, L., & Wang, Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1464159 · Cited by 12

Authors: Self, W. K., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Holtzman, David M.
ORCID: Self, Wade K.
Holtzman, David M.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2023-09
Volume: 29
Issue: 9
Pages: 2187-2199
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-023-02505-2
OpenAlex: W4386437808
Cited by: 381
References: 159
Citations by year: 2026: 91 · 2025: 140 · 2024: 134 · 2023: 15
FWCI: 14.09
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RF1NS090934, RF1AG047644)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U19AG069701)
Cure Alzheimer’s Fund
JPB Foundation
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, biomarkers, amyloid, tau protein, neuroinflammation, anti-amyloid antibodies, disease-modifying therapy, neuroimaging, fluid biomarkers, pathological staging, cognitive decline, therapeutic target, dementia
MeSH terms: Alzheimer Disease, Humans, Technology, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Emerging diagnostics and therapeutics for Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks